Agomelatine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Agomelatine: From Major Depressive Disorder to Melancholia
Report Focus: This report highlights Melancholia (rank 4, L1 evidence) as the most clinically and evidentially supported repurposing candidate. Although rank 1 by TxGNN score is benign paroxysmal torticollis of infancy (L5, Hold, no supporting evidence), the mechanistic alignment and breadth of literature for melancholia make it the most actionable prediction.
One-Sentence Summary
Agomelatine is a unique antidepressant combining melatonergic agonism (MT1/MT2) and 5-HT2C antagonism, approved in Europe for major depressive disorder (MDD) but not yet marketed in Taiwan. The TxGNN model predicts it may be particularly effective for Melancholia — a biologically distinct MDD subtype defined by profound anhedonia, morning worsening, and disrupted circadian rhythms — with 0 registered clinical trials specifically targeting this subtype but 20 publications providing a robust mechanistic and clinical evidence base.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major Depressive Disorder (EU approved as Valdoxan®; no Taiwan authorization) |
| Predicted New Indication | Melancholia |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L1 |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Taiwan Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Agomelatine’s mechanism of action is unlike any other antidepressant: it acts as a full agonist at MT1 and MT2 melatonin receptors — resynchronizing the biological clock — while simultaneously blocking 5-HT2C serotonin receptors, which enhances dopamine and norepinephrine release in the prefrontal cortex. This dual mechanism is documented across multiple preclinical and clinical studies and was confirmed by the drug’s EMA marketing authorization. Importantly, agomelatine achieves antidepressant efficacy without the sexual dysfunction, weight gain, or sleep architecture disruption typically associated with SSRIs and SNRIs.
Melancholia is a DSM-5 specifier for severe major depressive episodes, defined by profound anhedonia (inability to experience pleasure even to positive events), early morning awakening, diurnal mood variation with morning worsening, psychomotor disturbance, and disrupted HPA-axis activity. These clinical features map directly onto the pathways agomelatine targets: circadian resynchronization via MT1/MT2 agonism directly counteracts the characteristic early awakening and morning worsening, while enhanced DA/NE neurotransmission in the prefrontal cortex addresses anhedonia — a symptom domain where SSRIs consistently underperform. No other currently approved antidepressant addresses both circadian and hedonic deficits simultaneously.
The published literature robustly supports agomelatine’s efficacy in MDD, with increasing evidence for its anti-anhedonic properties specifically. The landmark 2018 Lancet network meta-analysis (Cipriani et al., 21 drugs, 522 trials, 116,477 participants) confirmed agomelatine’s favorable efficacy-acceptability balance. A 2025 narrative review (Serretti, PCN Reports) explicitly identifies agomelatine among drugs with “promising anti-anhedonic effects” — directly applicable to melancholia’s core symptomology. While no melancholia-specific RCTs currently exist, the mechanistic coherence and high-quality MDD evidence base are sufficient to support a “Proceed with Guardrails” decision.
Clinical Trial Evidence
Currently no related clinical trials registered specifically for agomelatine in melancholia.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29477251 | 2018 | Network Meta-Analysis (RCT-based) | Lancet | Among 21 antidepressants for acute MDD (522 trials, 116 K+ patients); agomelatine shows favorable efficacy and acceptability |
| 39684343 | 2024 | Systematic Review & Meta-Analysis | Int J Mol Sci | Agomelatine efficacy and safety in MDD comorbid with diabetes mellitus; supports broader clinical utility |
| 36253442 | 2023 | Systematic Review | Molecular Psychiatry | Network meta-analysis of antidepressants in MDD maintenance phase; agomelatine demonstrates durable benefit |
| 40129874 | 2025 | Narrative Review | PCN Reports | Agomelatine explicitly cited with “promising anti-anhedonic effects” alongside vortioxetine and ketamine — core relevance to melancholia |
| 41135546 | 2025 | Systematic Review | Lancet | RCT-based comparison of antidepressant physiological side-effect profiles; agomelatine’s cardiometabolic footprint among the most favorable |
| 37424409 | 2023 | Narrative Review | Clin Psychopharmacol Neurosci | Anhedonia as core MDD feature; reward processing deficits linked to suicidality; inflammation as moderator |
| 34419186 | 2021 | Review | Lancet Psychiatry | Circadian rhythm disruption as causal pathway in depressive disorders in young people; strongly supports agomelatine’s mechanistic fit for melancholia |
| 27508501 | 2016 | Safety Review | Psychother Psychosom | Critical review of newer-generation antidepressant safety; agomelatine’s hepatotoxicity and monitoring requirements detailed |
| 24033095 | 2013 | Review | Expert Opin Drug Safety | Agomelatine as melatonergic agonist + 5-HT2C antagonist; effective antidepressant with mild side-effect profile |
| 32568567 | 2020 | Review | Expert Opin Drug Discovery | Preclinical development history; first antidepressant with mechanism extending beyond monoaminergic neurotransmission |
Taiwan Regulatory Information
No regulatory records are available for agomelatine in Taiwan. The drug is not approved or marketed in Taiwan (未上市) with 0 TFDA authorizations on record.
For reference: Agomelatine is approved in the European Union as Valdoxan® (Servier, EU/1/08/499/001–007) for the treatment of major depressive episodes in adults, with mandatory hepatotoxicity monitoring as a condition of authorization.
Safety Considerations
Detailed TFDA warnings and contraindications are not available in the current evidence pack. The following is drawn from published literature:
- Hepatotoxicity: Dose-dependent liver enzyme elevations (ALT/AST) have been reported. Liver function tests are required at baseline and at weeks 3, 6, 12, and 24 of treatment. Agomelatine is contraindicated in patients with hepatic impairment.
- Pediatric use: Not recommended in patients under 18 years; no safety or efficacy data available in this population.
- CYP1A2 drug interactions: Concomitant use with potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) markedly increases agomelatine plasma exposure and is contraindicated.
Please refer to the EU SmPC (Valdoxan) for complete safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Agomelatine’s dual mechanism — MT1/MT2 circadian resynchronization plus 5-HT2C-mediated DA/NE enhancement — maps onto the pathophysiology of melancholia more precisely than any existing first-line antidepressant. High-quality systematic reviews and network meta-analyses confirm agomelatine’s efficacy in broader MDD populations, and the anti-anhedonic evidence specifically supports its application in the melancholic specifier.
To proceed, the following is needed:
- Dedicated prospective trials or enriched subgroup analyses in patients meeting DSM-5 melancholia specifier criteria
- Formal MOA documentation from DrugBank API (currently a data gap; DG002)
- Taiwan TFDA SmPC review for local contraindications and warnings (DG001, currently blocking safety screening)
- Pre-defined hepatotoxicity monitoring protocol (ALT/AST baseline + periodic checks per EU SmPC cadence)
- Regulatory pathway assessment for Taiwan market authorization, including bridging data strategy
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.